Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

about

Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread

P2860

Q58738833-A1E6F63A-BC8F-4A93-B5C6-49FC1058B349

P2860

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

Item

http://www.wikidata.org/entity/Q52568669

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Protection from cytomegaloviru ...... nt on neutralizing antibodies.

@en

Protection from cytomegaloviru ...... nt on neutralizing antibodies.

@nl

type

Item

label

Protection from cytomegaloviru ...... nt on neutralizing antibodies.

@en

Protection from cytomegaloviru ...... nt on neutralizing antibodies.

@nl

prefLabel

Protection from cytomegaloviru ...... nt on neutralizing antibodies.

@en

Protection from cytomegaloviru ...... nt on neutralizing antibodies.

@nl

P1476

Protection from cytomegaloviru ...... nt on neutralizing antibodies.

@en

P2093

Barbara Kropff

http://www.w3.org/2001/XMLSchema#string

Claire Atkinson

http://www.w3.org/2001/XMLSchema#string

Gary R McLean

http://www.w3.org/2001/XMLSchema#string

Ilona Baraniak

http://www.w3.org/2001/XMLSchema#string

Lyn Ambrose

http://www.w3.org/2001/XMLSchema#string

Megan McIntosh

http://www.w3.org/2001/XMLSchema#string

Michael Mach

http://www.w3.org/2001/XMLSchema#string

Paul D Griffiths

http://www.w3.org/2001/XMLSchema#string

Richard S B Milne

http://www.w3.org/2001/XMLSchema#string

Sylvie Pichon

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccine prevention of maternal cytomegalovirus infection

Immune correlates of vaccine protection against HIV-1 acquisition

Mechanism for neutralizing activity by the anti-CMV gH/gL monoclonal antibody MSL-109

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies.

B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.

Structural basis for the recognition of human cytomegalovirus glycoprotein B by a neutralizing human antibody

Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee.

Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies

Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

P31

scholarly article

P356

10.1073/PNAS.1800224115

http://www.w3.org/2001/XMLSchema#string

P407

English

P50

Matthew Reeves

P577

2018-04-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29686064

http://www.w3.org/2001/XMLSchema#string

P921

Cytomegalovirus

P932

6004462

http://www.w3.org/2001/XMLSchema#string

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

about

P2860

P2860

Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P50

P577

P698

P921

P932